Posted by Michael Wonder on 27 Dec 2023
Amgen provides regulatory update on the status of Lumakras (sotorasib)
26 December 2023 - FDA has issued a new post-marketing requirement.
Amgen announced today that the US FDA has completed its review of the company's supplemental new drug application seeking full approval of Lumakras (sotorasib).
